Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Levobetaxolol is a beta-blocker used to lower the pressure in the eye to treat conditions such as glaucoma. It was marketed as a 0.5% ophthalmic solution of levobetaxolol hydrochloride under...
- Mechanism
- Curator reviewed · 1 reference
The exact mechanism by which levobetaxolol lowers intraocular pressure is not known. It it thought that antagonism of β-adrenergic receptors may reduce the production of aqueous humour stimulated via the cyclic adenosine monophosphate-protein kinase A pathway. It is also thought that the vasoconstriction produced by antagonism of β adrenergic receptors reduces blood flow to the eye and therefore the ultrafiltration responsible for aqueous humour production. β1 selective antagonists are less effective than non-selective β adrenergic receptor antagonists because β2 receptors make up the bulk of the population in the eye. They do, however, come with the benefit of reduced respiratory complications.
- Primary indication
- Used in the treatment of open-angle glaucoma and ocular hypertension.Curator reviewed
- Formula / weight
- C18H29NO3 · 307.434 g/mol (avg)
- Also known as
- (S)-betaxolol
Resolves to
NWIUTZDMDHAVTP-KRWDZBQOSA-NSMILESCC(C)NC[C@H](O)COC1=CC=C(CCOCC2CC2)C=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Levobetaxolol, and which of those have an active Phase 3 trial?